The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes

  • Leonard NaymagonEmail author
  • Douglas Tremblay
  • Thomas Schiano
  • John Mascarenhas


Pylephlebitis, or suppurative thrombophlebitis of the portal vein, typically occurs in the context of an intraabdominal infection or abdominal sepsis. Antibiotics are the mainstay of treatment. The role of anticoagulation in the management of pylephlebitis is controversial, and data regarding its impact on outcomes is limited. The records of 67 consecutive patients with pylephlebitis treated at our institution over a 19 year period were retrospectively reviewed. Data was gathered regarding their baseline characteristics, presentations, management, and outcomes. Patients who did and did not receive anticoagulation were compared. Outcomes of interest included survival, portal vein thrombosis (PVT) resolution, development of chronic symptomatic portal hypertension, and major bleeding. Forty-seven patients received anticoagulation and 20 did not. The anticoagulated and non-anticoagulated groups did not differ significantly with respect to potential covariates or confounders. Anticoagulated patients had significantly higher rates of PVT resolution than non-anticoagulated patients (58% vs. 21%, p = 0.0201). This translated to lower rates of future chronic portal hypertensive symptoms among anticoagulated patients (11% vs. 47%, p = 0.0034). Anticoagulated patients had a trend toward improved survival however this improvement was not significant on multivariable analysis. There was no significant difference in rates of major bleeding between groups. Thrombophilia testing was common in this cohort however the occurrence of meaningful positive results was exceedingly low. Anticoagulation significantly improves the rate of PVT resolution, and significantly reduces the rate of chronic symptomatic portal hypertension, among patients with pylephlebitis. Treatment of pylephlebitis should incorporate the use of systemic anticoagulation whenever possible.


Pylephlebitis Thrombophlebitis Portal vein thrombosis (PVT) Splanchnic vein thrombosis (SVT) Intraabdominal infection Anticoagulation (AC) 



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.


  1. 1.
    Plemmons RM, Dooley DP, Longfield RN (1995) Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 21(5):1114–1120CrossRefGoogle Scholar
  2. 2.
    Kasper DL, Sahani D, Misdraji J (2005) Case records of the massachusetts general hospital. Case 25-2005: a 40-year-old man with prolonged fever and weight loss. N Engl J Med 353(7):713–722CrossRefGoogle Scholar
  3. 3.
    Kanellopoulou T, Alexopoulou A, Theodossiades G, Koskinas J, Archimandritis AJ (2010) Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis 42(11–12):804–811CrossRefGoogle Scholar
  4. 4.
    Soro Y (1948) Pylephlebitis and liver abscesses due to appendicitis. J Int Coll Surg 11(5):464–468Google Scholar
  5. 5.
    Choudhry AJ, Baghdadi YM, Amr MA, Alzghari MJ, Jenkins DH, Zielinski MD (2016) Pylephlebitis: a review of 95 cases. J Gastrointest Surg 20(3):656–661CrossRefGoogle Scholar
  6. 6.
    Baril N, Wren S, Radin R, Ralls P, Stain S (1996) The role of anticoagulation in pylephlebitis. Am J Surg 172(5):449–452 discussion 452-443 CrossRefGoogle Scholar
  7. 7.
    Wang YF, Chang CC, Lee TC, Shih IL, Lien WC, Chen SJ et al (2013) Recent trend of pylephlebitis in Taiwan: Klebsiella pneumoniae liver abscess as an emerging etiology. Infection 41(6):1137–1143CrossRefGoogle Scholar
  8. 8.
    Balthazar EJ, Gollapudi P (2000) Septic thrombophlebitis of the mesenteric and portal veins: CT imaging. J Comput Assist Tomogr 24(5):755–760CrossRefGoogle Scholar
  9. 9.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefGoogle Scholar
  10. 10.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829CrossRefGoogle Scholar
  11. 11.
    Connors JM (2017) Thrombophilia testing and venous thrombosis. N Engl J Med 377(12):1177–1187CrossRefGoogle Scholar
  12. 12.
    Zarrouk M, Salim S, Elf J, Gottsater A, Acosta S (2017) Testing for thrombophilia in mesenteric venous thrombosis—Retrospective original study and systematic review. Best Pract Res Clin Gastroenterol 31(1):39–48CrossRefGoogle Scholar
  13. 13.
    Gesner BM, Jenkin CR (1961) Production of heparinase by bacteroides. J Bacteriol 81:595–604Google Scholar
  14. 14.
    Bjornson HS, Hill EO (1973) Bacteroidaceae in thromboembolic disease: effects of cell wall components on blood coagulation in vivo and in vitro. Infect Immun 8(6):911–918Google Scholar
  15. 15.
    Martinod K, Wagner DD (2014) Thrombosis: tangled up in NETs. Blood 123(18):2768–2776CrossRefGoogle Scholar
  16. 16.
    Garrett A, Carnish E, Das N, Slome M, Measley R (2014) Once universally fatal: pylephlebitis. Am J Med 127(7):595–597CrossRefGoogle Scholar
  17. 17.
    Rhame FS, Maki DG (1976) Letter: septic nonsuppurative thrombophlebitis. Arch Surg 111(7):832CrossRefGoogle Scholar
  18. 18.
    Hoffman HL, Partington PF, Desanctis AL (1954) Pylephlebitis and liver abscess. Am J Surg 88(3):411–416CrossRefGoogle Scholar
  19. 19.
    Shaw PJ, Saunders AJ, Drake DP (1986) Case report: ultrasonographic demonstration of portal vein thrombosis in the acute abdomen. Clin Radiol 37(1):101–102CrossRefGoogle Scholar
  20. 20.
    Kearon C, Akl EA (2014) Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 123(12):1794–1801CrossRefGoogle Scholar
  21. 21.
    Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M et al (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120(2):490–497CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology and Medical Oncology, Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Division of Liver Diseases, Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations